/

Other

/

Advanz Pharma

Advanz Pharma

Advanz Pharma

Verified Nov 2026

Other

·

United Kingdom flag

London, England

·

Since 2018

Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.

Advanz Pharma

Verified Nov 2026

AT A GLANCE

Founded

2018

Headquarters

United Kingdom flag

London, England

Employees

500-1,000

Ownership

Advanz Pharma at a glance

Revenue

$500M-1B

Est. band

Employees

500-1,000

Founded

2018

Headquarters

London, England

Industries

Automotive

Electric Vehicles

Medical

Industrial Equipment

Overview

Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.

At a glance

Attribute

Detail

Founded

2018

Headquarters

London, England

Employees

500-1,000

Revenue

$500M-1B (estimated)

What Advanz Pharma makes

The company offers a diverse portfolio spanning medicines, specialty generics, biosimilars, and originator brands, with a focus on acquiring and commercializing legacy pharmaceutical compounds to serve wholesalers, distributors, hospitals, and pharmacies.

Latest developments

Company details

Advanz Pharma operates through subsidiaries including Boucher & Muir Pty Ltd serving the Australia, New Zealand, and South Pacific markets, and has secured over $1.17 billion in funding since its founding. Advanz Pharma was founded in 2018, has an estimated 500-1,000 employees, and is headquartered in London, England.

Frequently asked questions

What does Advanz Pharma do?

Advanz Pharma is a London-based pharmaceutical company founded in 2018 (rebranded from Concordia Healthcare) with 500-1,000 employees and revenue between $500 million and $1 billion. It develops specialty, hospital, and rare disease medicines across therapeutic areas including hepatology, gastroenterology, and oncology, operating in over 90 countries. The company has recently acquired global rights to the rare disease specialty brand Zavesca and partnered with Alvotech to commercialize additional biosimilars in Europe.

Where is Advanz Pharma headquartered?

Advanz Pharma is headquartered in London, England.

When was Advanz Pharma founded?

Advanz Pharma was founded in 2018.

How big is Advanz Pharma?

Advanz Pharma has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

London, England (HQ)Headquarters · England, United Kingdom
London, England (HQ)London, England, United KingdomHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.